Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Kathleen Dungan
- Target Recruit Count
- 8
- Registration Number
- NCT01970462
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 50
- Registration Number
- NCT01963845
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 36
- Registration Number
- NCT01951339
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
- Conditions
- Interventions
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Michael A. Nauck
- Target Recruit Count
- 16
- Registration Number
- NCT01937598
- Locations
- 🇩🇪
Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany
A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test
- Conditions
- Interventions
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 34
- Registration Number
- NCT01936025
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1231
- Registration Number
- NCT01930188
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Zaporizhia, Ukraine
Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
- Conditions
- Interventions
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 61
- Registration Number
- NCT01928199
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 407
- Registration Number
- NCT01907854
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Lund University
- Target Recruit Count
- 12
- Registration Number
- NCT01901861
- Locations
- 🇸🇪
Department of Clinical Science Lund,Lund University, Lund, Sweden
Triple Therapy in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 64
- Registration Number
- NCT01895569
- Locations
- 🇮🇹
IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.